Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comment
. 2005;7(5):189-90.
doi: 10.1186/ar1820. Epub 2005 Aug 22.

DAS28: a useful instrument to monitor infliximab treatment in patients with rheumatoid arthritis

Piet L C M van Riel  1 , Jaap Fransen
Affiliations
Comment

DAS28: a useful instrument to monitor infliximab treatment in patients with rheumatoid arthritis

Piet L C M van Riel et al. Arthritis Res Ther. 2005.

Abstract

The Disease Activity Score using 28 joint counts (DAS28) has been developed in a cohort of patients with rheumatoid arthritis in which only conventional anti-rheumatic treatments were used. It has extensively been validated to monitor disease activity in daily clinical practice as well as in clinical trials. The study of Vander Cruyssen and colleagues showed that the DAS28 correlated best with the decisions of rheumatologists to increase the infliximab dose because of insufficient response. This result once more confirms the validity of the DAS28 to monitor disease activity in patients with rheumatoid arthritis and to titrate treatment with biologicals.

PubMed Disclaimer

Comment on

References

    1. Vander Cruyssen B, Van Looy S, Wyns B, Westhovens R, Durez P, Van den Bosch F, Veys EM, Mielants H, De Clerck L, Peretz A, et al. DAS28 reflects best the physician's clinical judgement of response to infliximab therapy in rheumatoid arthritis patients: validation of the DAS28 score in patients under infliximab treatment. Arthritis Res Ther. 2005;7:R1063–R1071. doi: 10.1186/ar1787. - DOI - PMC - PubMed
    1. Durez P, Van den Bosch F, Corluy L, Veijs EM, De Clerck L, Peretz A, Malaise M, Devogelaer JP, Vastesaeger N, Geldhof A, et al. A dose adjustment in patients with rheumatoid arthritis not optimally responding to a standard dose of infliximab of 3 mg/kg every 8 weeks can be effective: a Belgian prospective study. Rheumatology. 2005;44:465–468. doi: 10.1093/rheumatology/keh494. - DOI - PubMed
    1. Heijde van der DMFM, Hof van't MA, Riel van PLCM, Theunisse HAM, Lubberts EW, Leeuwen van MA, Rijswijk van MH, Putte van de LBA. Judging disease activity in clinical practice in rheumatoid arthritis. First step in the development of a 'disease activity score'. Ann Rheum Dis. 1990;49:916–920. - PMC - PubMed
    1. Prevoo MLL, Hof van't MA, Kuper HH, Leeuwen van MA, Putte van de LBA, Riel van PLCM. Modified disease activity scores that include twenty-eight-joint counts: development and validation in a prospective longitudinal study of patients with rheumatoid arthritis. Arthritis Rheum. 1995;38:44–48. - PubMed
    1. Fransen J, Stucki G, Riel van PLCM. Rheumatoid arthritis measures. Arthritis Rheum (Arthritis Care Res) 2003;49:214–224. doi: 10.1002/art.11407. - DOI

MeSH terms